Important Legal Developments for Applied Therapeutics Investors
Investors in Applied Therapeutics, Inc. (NASDAQ: APLT) should be aware of significant developments regarding an ongoing class action securities lawsuit initiated by Levi & Korsinsky, LLP. This class action aims to recover losses for those impacted by alleged securities fraud that occurred between specific dates.
Understanding The Class Action Lawsuit
The class action lawsuit represents investors who may have faced financial losses as a result of misleading information or lack of transparency regarding Applied Therapeutics operations. If you were affected, it’s vital to know that there’s a deadline approaching to act. The deadline for appointing a lead plaintiff in this case is set for February 18, 2025.
What Constitutes Class Inclusion?
To be considered part of this class action, an investor must have purchased stocks during the time frame in question. The aim is to catalog losses that resulted from fluctuations in stock price, driven by the disclosures surrounding the company's new drug application (NDA) for govorestat, among other issues.
Details of the Case
In recent disclosures, Applied Therapeutics revealed serious setbacks. On November 27, 2024, the company faced a Complete Response Letter (CRL) from the FDA regarding its NDA for govorestat. This letter indicated that the FDA was unable to approve the application due to clinical deficiencies, which caused a drastic decline in the stock price.
Stock Price Volatility
On November 26, 2024, shares of APLT were priced at $10.21. Following the company's news about the CRL, the stock saw a sharp decline to $8.57 the next day. Subsequently, the price fell to $2.03 and $1.75 by early December. Such a downturn indicated an overall decline of over 80%, significantly impacting investors. The decline intensified when it was revealed that the company received a warning letter from the FDA about clinical trial issues.
Next Steps for Affected Investors
Investors affected by the fluctuations in the stock price have an opportunity to potentially recover losses, regardless of whether they choose to act as lead plaintiffs or not. It’s crucial to act before the cutoff date on February 18, 2025, to secure your standing in the case.
Cost-Free Participation
The good news is that participating in this class action comes at no cost to the investors. If you qualify as a class member, you can pursue compensation without dealing with out-of-pocket expenses. There is no obligation to join the lawsuit, allowing individuals to weigh their options freely.
Why Choose Levi & Korsinsky?
With two decades of successful litigation experience, Levi & Korsinsky has earned its reputation in the field of securities litigation. The firm has recovered hundreds of millions of dollars for shareholders and is recognized as one of the top law firms for class actions in the U.S. Having a dedicated team of over 70 professionals allows them to effectively represent investor interests.
Contact Information
If you believe you have suffered losses due to the issues surrounding Applied Therapeutics, consider reaching out to Levi & Korsinsky for guidance. Joseph E. Levi, Esq. and his team are available to discuss your situation and help you navigate your options.
Frequently Asked Questions
What is the purpose of this class action lawsuit?
The class action lawsuit seeks to recover financial losses incurred by investors of Applied Therapeutics due to alleged misleading information that affected the stock price.
How can I participate in the class action?
You must indicate your intention to participate before the February 18, 2025, deadline. This can typically be done by contacting the law firm handling the case.
What does it cost to join the lawsuit?
Joining the class action carries no financial obligation for participants; any costs are typically absorbed by the law firm.
What are the significant events leading to the lawsuit?
Key events include the CRL from the FDA regarding the new drug application and subsequent declines in the stock price following this announcement and related disclosures.
Who can I contact for more information?
For more information, you can reach out directly to the legal team at Levi & Korsinsky, which is committed to assisting affected investors.
